Prot# CLBH589BUS58: Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients with Primary Myelofibrosis (PMF), Post-Essential Thrombocythemia (ET) Myelofibrosis and Post-Polycythemia Vera (PV) Myelofibrosis

Project: Research project

Project Details

StatusFinished
Effective start/end date11/12/091/1/11

Funding

  • PRA Health Sciences (CLBH589BUS58)
  • Novartis Pharmaceuticals Corporation (CLBH589BUS58)